


## **BIOPHARMACEUTICALS**



# Demonstration of Increased Sensitivity with Reduced Trastuzumab Using a 1.5 mm ID Column

286-BIC



### **PEAK IDENTITIES**

LC = Light Chain HC = Heavy Chain

#### **TEST CONDITIONS:**

Column: HALO 1000 Å Diphenyl, 2.7 μm, 1.5 x 150 mm

Part Number: 9212X-702

Column: HALO 1000 Å Diphenyl, 2.7 μm, 2.1 x 150 mm

Mobile Phase A: Water/0.1% DFA

B: 50% Acetonitrile/50% n-propanol/0.1%

DFA

Gradient: Time (min) %B 0.0 27 40.0 36 40.1 27 45.0 27

Flow Rate: 0.2 mL/min for 1.5 mm ID

0.4 mL/min for 2.1 mm ID

Back Pressure: 252 bar (1.5 mm)

272 bar (2.1 mm)

Temperature: 60 °C

Injection Volume: 3 µL of 1.0 mg/mL reduced and

alkylated trastuzumab

Sample Solvent: Water/0.1% TFA LC System: Shimadzu Nexera X2 MS System: ThermoFisher Q Exactive

#### **MS CONDITIONS:**

Spray Voltage (kV): 3.8

Capillary temperature: 320 °C

Sheath gas: 35 Aux gas: 10 RF lens: 50

A separation of reduced and alkylated Trastuzumab is performed on a HALO 1000 Å Diphenyl column. Switching to a 1.5 mm ID column from the 2.1 mm ID provides a significant increase in sensitivity for the reduced and alkylated Trastuzumab along with a reduced flow rate. This increase in sensitivity can be achieved by using a 1.5 mm ID column in conjunction with optimized tubing post-column which provides a cheaper route for increased sensitivity without the investment into a specialized HPLC system.



